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Abstract: The abnormal development or disruption of the lymphatic vasculature has been implicated
in metabolic and hypertensive diseases. Recent evidence suggests that the offspring exposed to
preeclampsia (PE) in utero are at higher risk of long-term health problems, such as cardiovascular
and metabolic diseases in adulthood, owing to in utero fetal programming. We aimed to investigate
lymphangiogenic activities in the lymphatic endothelial progenitor cells (LEPCs) of the offspring
of PE. Human umbilical cord blood LEPCs from pregnant women with severe PE (n = 10) and
gestationally matched normal pregnancies (n = 10) were purified with anti-vascular endothelial
growth factor receptor 3 (VEGFR3)/podoplanin/CD11b microbeads using a magnetic cell sorter
device. LEPCs from PE displayed significantly delayed differentiation and reduced formation of
lymphatic endothelial cell (LEC) colonies compared with the LEPCs from normal pregnancies. LECs
differentiated from PE-derived LEPCs exhibited decreased tube formation, migration, proliferation,
adhesion, wound healing, and 3D-sprouting activities as well as increased lymphatic permeability
through the disorganization of VE-cadherin junctions, compared with the normal pregnancy-derived
LECs. In vivo, LEPCs from PE showed significantly reduced lymphatic vessel formation compared to
the LEPCs of the normal pregnancy. Gene expression analysis revealed that compared to the normal
pregnancy-derived LECs, the PE-derived LECs showed a significant decrease in the expression
of pro-lymphangiogenic genes (GREM1, EPHB3, VEGFA, AMOT, THSD7A, ANGPTL4, SEMA5A,
FGF2, and GBX2). Collectively, our findings demonstrate, for the first time, that LEPCs from PE
have reduced lymphangiogenic activities in vitro and in vivo and show the decreased expression
of pro-lymphangiogenic genes. This study opens a new avenue for investigation of the molecular
mechanism of LEPC differentiation and lymphangiogenesis in the offspring of PE and subsequently
may impact the treatment of long-term health problems such as cardiovascular and metabolic
disorders of offspring with abnormal development of lymphatic vasculature.
Keywords: lymphatic endothelial progenitor cells; lymphangiogenesis; differentiation; preeclampsia
1. Introduction
Preeclampsia (PE), a complication associated with 5–8% of pregnancies worldwide, is a
hypertensive disease induced during pregnancy that is associated with systemic vasculopa-
thy and multi-organ failure. It is known that long-term abnormalities in the fetus in utero
may contribute to the subsequent development of adulthood disease in the offspring [1,2],
and recent epidemiologic studies have indicated that the offspring of preeclamptic mothers
display altered disease susceptibility [3]. Previous studies have demonstrated that the
offspring of preeclamptic mothers have a higher risk of cardiovascular disease [4,5], hyper-
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tension [6,7], stroke [8], metabolic disturbances such as diabetes [9,10] and obesity [11–13],
as well as increased susceptibility to inflammatory conditions [14] such as asthma [15,16].
The mechanism by which in utero fetal exposure to PE results in the reprograming of
fetal physiology and contributes to disease susceptibility is largely unknown. However,
several studies have suggested that in utero fetal programming that compromises the
intrauterine environment may permanently alter the structure and function of the biological
system of the fetus, ultimately increasing the individual’s susceptibility to disease later
in life. Previous studies have reported epigenetic modifications and/or altered gene
expression in the fetal endothelial progenitor cells (EPCs) exposed to PE in utero. These
changes were associated with diminished proliferation, increased senescence, or abnormal
endothelial cell function [17–21]. Therefore, changes in cellular behavior that culminate
in dysfunctional angiogenesis may serve as one of the possible mechanisms underlying
compromised in utero programming in the case of severe PE [22–25].
The lymphatic vasculature is a network of vessels formed by the lymphatic endothelial
cells (LECs), and is traditionally known to maintain fluid homeostasis, absorb lipids from
the intestine, and transport immune and antigen-presenting cells from inflammatory tissues
to lymph nodes [26,27]. Growing evidence suggests the involvement of the lymphatic
system in the modulation of the inflammatory response [28]. The lymphatic channel
regulates peripheral immune tolerance by facilitating the entry of antigens and antigen-
presenting cells into the immune system, controlling immune cell trafficking, and inducing
T cell tolerance [29–32]. In particular, abnormal or dysfunctional lymphangiogenesis has
been implicated in chronic inflammatory disease [33–35], autoimmune diseases [34,36],
and metabolic disorders such as diabetes and obesity [37,38].
Angiogenesis and lymphangiogenesis share many common angiogenic signaling
pathways. Therefore, abnormal lymphangiogenesis is often reported in pathophysiologies
with dysfunctional angiogenesis [39–41]. The pathophysiology of PE is associated with
dysfunctional angiogenesis, including the upregulated expression of anti-angiogenic factors
that induce systemic endothelial dysfunction, thereby result in hypertension, proteinuria,
and other systemic manifestations. We have previously reported significant abnormal
lymphatic development in the decidua of preeclamptic woman [20]. However, less is
known about the adverse effect of PE on lymphangiogenesis in leading to an unhealthy
lymphatic system.
Here, we hypothesized that exposure to PE may exert significant adverse effects on
the lymphatic endothelial progenitor cells (LEPCs) of the offspring, leading to abnormal
lymphangiogensis. The functional impairment in the LEPCs of the offspring of preeclamp-
tic mothers may form part of the mechanism underlying in utero programming, potentially
producing health effects later in adult life. We show that the potential of LEPCs to differ-
entiate into LECs is reduced, and the lymphangiogenic function of LECs is significantly
diminished, in PE both in vitro and in vivo. We discuss the potential role of differentially
expressed lymphangiogenesis-associated genes in offspring’s health.
2. Results
2.1. Isolation and Characterization of Human Cord Blood-Derived VEGFR3+/Pod+/CD11b+ Cells
as LEPCs and the Induction of Their Differentiation into LECs
To compare the lymphangiogenic functional capacity of LEPCs derived from PE
and normal pregnancies, we isolated the vascular endothelial growth factor receptor
3 (VEGFR3)+/podoplanin (Pod)+/CD11b+ cells from the mononuclear cells of human
cord blood via magnetic-activated cell sorting (Figure 1A). Upon culturing in EGM-2 in
the presence of fibronectin, the VEGFR3+/Pod+/CD11b+ cells differentiated into LECs,
which expressed the LEC-specific markers LYVE-1 and Prox1 (Figure 1B). These results
demonstrate that VEGFR3+/Pod+/CD11b+ cells from cord blood can serve as LEPCs that
can differentiate into LECs.
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Figure 1. Isolation and characterization of the VEGFR3+/Pod+/CD11b+ cells. (A) The VEGFR3+/Pod+/CD11b+ cells were
isolated by density-gradient centrifugation using Biocoll for 30 min at 400× g, washed thrice with phosphate-buffered saline,
and purified by positive selection using VEGFR3+/Pod+/CD11b+ microbeads and a magnetic cell sorter device. (B) The
VEGFR3+/Pod+/CD11b+ cells from preeclamptic (n = 10) and normal (n = 10) pregnancies were differentiated into ten
LECs, respectively, and the expression of LEC-specific markers, Prox1 and LYVE1, was confirmed by immunofluorescence
staining. MNC, mononuclear cell; MACS, magnetic-activated cell sorting; PE, preeclampsia; LEC, lymphatic endothelial cell.
2.2. VEGFR3+/Pod+/CD11b+ LEPCs from Women with PE Show Diminished Differentiation
into LECs
We compared the differentiation ability of the LEPCs derived from woman with PE
and those with normal pregnancy by investigating the time required for their differenti-
ation into LECs and evaluating the number and size of differentiated LEC colonies. The
VEGFR3+/Pod+/CD11b+ LEPCs from normal pregnancies differentiated into LECs after 9
days of culture (Figure 2A,B). However, it took 14 days for the VEGFR3+/Pod+/CD11b+
LEPCs from PE-complicated pregnancies to differentiate into LECs (Figure 2A,B). Moreover,
both the number and size of the LEC colonies were decreased in the PE group compared
with those in the normal pregnancy group on the same differentiation days (Figure 2C,D).
These results suggest that the VEGFR3+/Pod+/CD11b+ LEPCs from woman with PE have
a diminished differentiation capability compared to those from normal pregnancies.
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Figure 2. VEGFR3+/Pod+/CD11b+ lymphatic endothelial progenitor cells (LEPCs) derived from preeclamptic women
show decreased differentiation potency. (A) Morphological assessment of (VEGFR3+/Pod+/CD11b+) LEPC differentiation
into LECs upon culture with fibronectin (10 µg/mL). The arrowheads indicate the differentiated LEC colonies. Images were
viewed at 100×magnification. (B) Quantitative analysis of the differentiation days. The data are presented as the mean ±
standard error (SE). **, p < 0.05 vs. normal. (C) Morphological assessment of LEPC differentiation into LECs upon culture
with fibronectin (10 µg/mL). The dashed-line circles indicate the differentiated LEC colonies. Images were viewed at 40×
magnification. (D) Quantitative analysis of differentiated LEC colonies. All experiments were performed in ten different cell
lines. The data are presented as the mean ± SE. **, p < 0.05 vs. normal. LEC, lymphatic endothelial cell; PE, preeclampsia.
2.3. LECs Derived from VEGFR3+/Pod+/CD11b+ LEPCs of PE Show Decreased Lymphangiogenic
Activities In Vitro
We next analyzed the in vitro lymphangiogenic activities of LECs differentiated from
the VEGFR3+/Pod+/CD11b+ LEPCs from women with PE and those with normal pregnan-
cies. The LECs were able to form capillary-like tubes on the Matrigel. The tube connection
and network formation were decreased in the PE group compared to those of the nor-
mal pregnancy group. Furthermore, the length and area of the tubes formed by the PE
group LECs were diminished compared to those of the normal pregnancy control LECs
(Figure 3A).
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Figure 3. The lymphangiogenic functions of LECs derived from preeclamptic and normal pregnancies. (A) Tubular network
formation of the LECs derived from normal and PE pregnancies on Matrigel was photographed and quantified at 24 h.
(B) Migration was quantified by counting the cells that migrated to the lower surface of the filters via optical microscopy at
200×magnification. (C) LECs (1 × 103 cells) were seeded into a 96-well plate in triplicate for each condition. At the end of
the incubation, the supernatants were removed, and each well was treated with 150 µL DMSO. The absorbance value (OD)
of each well was measured at 490 nm. All experiments were performed in triplicate with three different cell lines. LEC,
lymphatic endothelial cell; DMSO, dimethyl sulfoxide; PE, preeclampsia. **, p < 0.01 vs. normal.
In the migration assay, the number of transmigrated cells was significantly reduced in
the PE group (Figure 3B). Furthermore, the proliferation activity of the LECs from the PE
group was decreased compared to that of the LECs from the normal pregnancy group at 48
and 72 h (Figure 3C).
After wounding, the maximal migration of the cells into the wounded area was
reduced in the PE group LECs (Figure 4A). The remnant wound area after 16 h was larger
for the PE group than for the normal pregnancy group (Figure 4B). Moreover, the LECs from
the PE group showed a reduced adhesion activity (Figure 4C,D). These results indicate
that LECs differentiated from VEGFR3+/Pod+/CD11b+ LEPCs of PE have decreased
lymphangiogenic activities in vitro and may be associated with the abnormal development
of lymphatic vessels in the offspring of PE.
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Figure 4. LECs derived from preeclamptic pregnancies show reduced wound healing and adhesion
activity. (A,B) LECs were seeded on 35-mm dishes. The confluent cell layer was scratched using a
micropipette tip and washed to remove any debris. Images were captured at 0 and 16 h after wound-
ing. For quantitative analysis, five fields per plate were photographed, and the distances between
the front lines were measured using ImageJ. (C,D) A 96-well plate was coated overnight (4 ◦C) with
0.1 mg/mL human fibronectin. LECs in an adhesion buffer were seeded at 105 cells/well in 100-µL
volume and incubated for 30 min at 37 ◦C. Cell adhesion was quantified by counting the cells that
attached to the fibronectin-coated matrix using optical microscopy at 200×magnification. All data
are presented as the mean ± standard error (SE) from three different cell lines performed in triplicate.
**, p < 0.01 vs. normal. LEC, lymphatic endothelial cell; PE, preeclampsia.
2.4. LECs Differentiated from VEGFR3+/Pod+/CD11b+ LEPCs of PE Present Reduced 3D
Lymphatic Sprouting
We next compared the sprouting ability of the LECs differentiated from LEPCs from
preeclamptic and normal pregnancies. After 5 days of culture, the cumulative sprout
length of the 3D-bead LECs differentiated from the preeclamptic pregnancy-derived
VEGFR3+/Pod+/CD11b+ LEPCs was significantly reduced compared to that of the LECs ob-
tained from the normal pregnancy-derived LEPCs (Figure 5A,B). In addition, the number of
sprouts emerging from the LECs of the PE group was also decreased in the spheroid sprout-
ing assay (Figure 5C,D). These observations provide evidence that LECs differentiated
from VEGFR3+/Pod+/CD11b+ LEPCs of PE exhibit disrupted lymphangiogenic activity.
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Figure 5. LECs derived from preeclamptic pregnancies show suppressed lymphatic vessel sprouting and lymphangiogenic
function in vitro. (A) In vitro 3D lymphangiogenesis with fibrin gel-embedded microbeads of LECs. (B) The cumulative
length of all sprouts originating from an individual spheroid was quantified after 5 days. **, p < 0.01 vs. normal. (C) LEC
spheroids were embedded in 20% Matrigel-containing fibrin gels and cultured for 48 h. Spheroids were stained for PECAM-
1. (D) Quantification of sprout number. All data are presented as the mean ± standard error (SE) from three different cell
lines with n = 7 per group per experiment. **, p < 0.01 vs. normal. LEC, lymphatic endothelial cell; PE, preeclampsia.
2.5. LECs Differentiated from VEGFR3+/Pod+/CD11b+ LEPCs of PE Show Increased Lymphatic
Vessel Permeability
VE-cadherin is known to mediate the endothelial adhesion required to form inter-
cellular junctions and preserve lymphatic vessel structure and integrity. We investigated
whether the localization of VE-cadherin in cell–cell junctions was altered in LECs of PE
compared to normal. In the LECs derived from normal pregnancies, VE-cadherin was
detected at the plasma membrane in a linear pattern at the cell border. In contrast, the LECs
derived from preeclamptic pregnancies displayed decreased expression of VE-cadherin
at the plasma membrane, and a disrupted linear pattern (Figure 6A). In addition, com-
pared to the normal pregnancy-derived LECs, the preeclamptic pregnancy-derived LECs
showed an increase in FITC-dextran permeability in a time-dependent manner (Figure 6B).
These results indicate that LECs derived from VEGFR3+/Pod+/CD11b+ LEPCs of PE show
increased lymphatic permeability by disorganizing lymphatic VE-cadherin junctions.
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Figure 6. LECs derived from preeclamptic pregnancies show increased permeability through the disorganization of
lymphatic VE-cadherin junctions. (A) Confluent LECs were fixed and stained with anti-VE-cadherin antibody. The arrows
indicate the disruption of the VE-cadherin junction at the plasma membrane. (B) FITC-dextran permeability was evaluated.
The experiments were performed in triplicate with three different cell lines. The data are presented as the mean ± standard
error (SE). **, p < 0.01 vs. normal. PE, preeclampsia.
2.6. VEGFR3+/Pod+/CD11b+ LEPCs from Women with PE Show Decreased Lymphangiogenic
Activity In Vivo
Next, we assessed the differentiation activity and lymphatic vessel formation of
VEGFR3+/Pod+/CD11b+ LEPCs from PE and normal pregnancy in vivo. Matrigel contain-
ing human VEGFR3+/Pod+/CD11b+ LEPCs was subcutaneously injected into C57/BL6
mice. After 14 days, the plugs were sectioned and stained for human LEC- and lymphatic
vessel-specific markers, podoplanin and LYVE-1, respectively. The PE-derived LEPCs
showed reduced differentiation activity into LECs and a significantly lower density of
podoplanin/LYVE1-positive lymphatic vessels compared to the normal pregnancy-derived
LEPCs (Figure 7A). Quantification of podoplanin/LYVE-1-positive lymphatic structures
confirmed that vessel density was significantly reduced in PE-derived LEPCs as com-
pared with normal (Figure 7B). Overall, our results indicate that PE-derived LEPCs exert
diminished lymphangiogenic activity in vivo.
Figure 7. VEGFR3+/Pod+/CD11b+ lymphatic endothelial progenitor cells (LEPCs) derived from preeclamptic pregnancies
show decreased LEC differentiation and lymphatic vessel formation in vivo. (A) Seven-week-old male C57/BL6 mice
were subcutaneously injected with 0.6 mL Matrigel containing 5 × 104 human LEPCs. After 14 days, the plugs were
removed and washed with PBS. Plug sections were used to identify the differentiated LEPCs using anti-LYVE1 (green) and
anti-podoplanin (red) antibodies. (B) Quantitative assessment of the LYVE1- and CD31-positive lymphatic vessels per field
for each section. The experiments were performed in triplicate with three different cell lines. The data are presented as the
mean ± standard error (SE). **, p < 0.01 vs. normal. PE, preeclampsia. Scale bar, 200 µm, 100 µm.
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2.7. Gene Expression Analysis of LECs Derived from LEPCs of Preeclamptic Women
We next used RNA-sequencing to investigate the changes in gene expression related
to the dysfunctional lymphangiogenesis observed in PE. As shown in Figure 8A, the
expression of GREM1, EPHB3, VEGFA, AMOT, THSD7A, ANGPTL4, SEMA5A, FGF2, and
GBX2 was significantly down-regulated in the LECs differentiated from the preeclamptic
pregnancy-derived LEPCs. The levels of these genes were further confirmed by RT-qPCR
and found to be significantly down-regulated in the LECs derived from preeclamptic
pregnancies (Figure 8B,C). These results suggest that the down-regulated expression of
various lymphangiogenesis-related genes may be related to the decreased lymphangiogenic
function of LECs from preeclamptic pregnancy.
Figure 8. RNA-sequencing for gene expression analysis using LECs derived from normal and preeclamptic pregnan-
cies. (A) Cluster of downregulated (four-fold) lymphangiogenesis-related genes in preeclamptic pregnancy-derived LECs
(n = 3) versus normal LECs (n = 3). (B,C) RT-qPCR analysis of the lymphangiogenesis-related genes. Gene expression
was normalized to GAPDH. N-LEC, normal pregnancy-derived lymphatic endothelial cell; PE-LEC, the preeclamptic
pregnancy-derived lymphatic endothelial cell. **, p < 0.01 vs. N-LEC.
3. Discussion
PE is known to exert adverse long-lasting effects on the offspring and contribute to
cardiovascular, metabolic, and neurological diseases. However, the underlying mechanism
is poorly understood. The most promising hypothesis is that suboptimal intrauterine
environments during pregnancy with PE may permanently alter the organ structure and
biological feedback mechanism of the fetus, increasing the individual’s susceptibility
to disease [42,43], and that stem cells may be involved in the influence of the in utero
environment on the subsequent risk of disease onset in adult life [44,45].
The present study demonstrates that in utero exposure to PE is associated with
the decreased differentiation of cord blood-derived LEPCs into LECs, as well as the im-
paired lymphangiogenic functions of LECs in vitro and in vivo. In addition, dysfunc-
tional lymphangiogenesis in PE was associated with the downregulated expression of
pro-lymphangiogenic genes (Figure 9). These findings indicate the formation of an abnor-
mal lymphatic system in the offspring exposed to PE, which may then be associated with
the adverse health conditions of the offspring later in life.
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Figure 9. Proposed model describing the differentiation of LEPCs to LECs under preeclamptic and normal pregnancy
conditions. The differentiation of the cord blood-derived LEPCs to LECs was significantly reduced under preeclamptic
pregnancy conditions compared to normal pregnancy conditions. Moreover, the LECs differentiated from the preeclamptic
pregnancy-derived LEPCs displayed decreased lymphatic vessel formation activity. Dysfunctional lymphangiogenesis in
preeclamptic pregnancy-derived cells was associated with the downregulated expression of pro-lymphangiogenic genes.
Lymphangiogenesis, that is the formation of new lymphatic vessels from preexisting
ones, involves the proliferation, migration, and tube formation of LECs. Growing evidence
has highlighted the contribution of abnormal lymphangiogenesis to the pathogenesis of
cardiovascular, metabolic, and neurodevelopmental diseases that are common in offspring
exposed to PE. For example, Viven et al. reported severely impaired cardiac regenera-
tion in the absence of a functional lymphatic network in adult zebrafish hearts. These
authors revealed an association between the absence of a functional lymphatic vascular
system and cardiac hypertrophy, metabolic disruption, and inflammation [46]. Moreover,
Yuuki et al. demonstrated that lymphangiogenesis is related to ischemia-induced heart
failure and reperfusion. They found that inhibition of the endogenous lymphangiogenesis
response could exacerbate ischemia-induced heart failure [47]. Lymphatic malfunction
also contributes to adult-onset obesity [48,49]. Harvey et al. revealed that compromised
lymphatic vascular integrity was the cause of the excessive accumulation of fat in Prox1+/−
mice, which became progressively obese with age [49]. In relation to neurodevelopmental
diseases, malfunction of the lymphatic vessel has been associated with autism spectrum
disorder, which is more common in offspring exposed to PE [50,51]. In light of these
previous reports, the present study provides important evidence that PE is a critical factor
related to dysfunctional lymphangiogenesis in offspring, mediated via a reduction in the
lymphangiogenic capacity and function of LEPCs and LECs, which may substantially affect
the long-term health of offspring.
We demonstrated that the dysfunctional lymphangiogenesis in PE is associated with
the downregulated expression of lymphangiogenesis-related genes, including GREM1,
EPHB3, VEGFA, AMOT, THSD7A, ANGPTL4, SEMA5A, FGF2, and GBX2. Previous studies
have highlighted the important functions of these genes. These genes are closely asso-
ciated with angiogenesis and lymphangiogenesis, and differential expression may alter
the function and subsequently affect disease susceptibility such as cardiovascular and
metabolic disease.
Gremlin 1 (GREM1) binds to VEGFR2 and promotes the proliferation, migration,
and angiogenic sprout formation of endothelial cells by tyrosine phosphorylation and
subsequent activation of downstream molecules [52]. The gremlin-VEGFR2 axis was re-
ported to be closely associated with angiogenesis in both physiological and pathological
processes [53]. In addition, knockdown of GREM1 suppresses cell growth and angiogene-
sis [54].
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Ephrin type-B receptor 3 (EPHB3) is critically important for the remodeling of the
embryonic vascular system; it controls the migration, adhesion, and sprouting behavior of
endothelial cells in vitro in a similar way as angiopoietin 1 (Ang1) and VEGF [55]. EPHB3
is also involved in immune cell activation and trafficking and is related to the pathogenesis
of various diseases, including immune-mediated conditions, cancer, atherosclerosis, and
central nervous system diseases [56]. Moreover, EPHB3 expressed in vascular endothelial
cells regulates angiogenesis in peripheral nerve injury [57].
Down regulation of VEGFA (vascular endothelial growth factor A) inhibits angio-
genesis and lymphangiogenesis [58]. VEGFA promotes lymphangiogenesis and high
endothelial venule expansion in lymph nodes [59]. K14 Vegf-A Tg Vegfr1 tk(−/−) mice
exhibit a remarkable decrease in lymphangiogensis as well as angiogenesis in subcutaneous
tissues [60].
AMOT (angiomotin) has been shown to regulate endothelial cell migration during em-
bryonic angiogenesis [61,62]. Anti-AMOT antibodies significantly decreased the number of
endothelial filopodia and inhibited vessel migration during retinal angiogenesis in vivo [63].
DNA vaccine targeting AMOT also inhibits angiogenesis and tumor growth [64].
Thrombospondin type I domain-containing 7A (THSD7A) promotes endothelial cell
migration and tube formation in angiogenesis [65,66]. Knockdown of Thsd7a disrupted
angiogenic sprouting via Notch-dll4 signaling during zebrafish development [67,68].
Angiopoietin like 4 (ANGPTL4) is known as the fasting-induced adipose factor (FIAF)
and is related to lymphatic endothelial function. LEC functions were severely reduced in
mice without ANGPTL4 expression, and ANGPTL4 mutants showed dilated and blood-
filled lymphatics, which were aberrantly connected to blood vessels [69]. ANGPTL4 also
promotes angiogenesis in a mouse model of acute ischemic stroke [70].
SEMA5A, a member of the semaphoring V subfamily, increases endothelial cell migra-
tion, proliferation and promotes angiogenesis [71]. Null mutation of SEMA5A results in
defective remodeling of the cranial vascular system in mice [72].
FGF2, also known as basic fibroblast growth factor (bFGF), regulates lymphangiogen-
esis and vascular permeability [73,74], and induces corneal blood and lymphatic vessel
growth [75]. Reciprocal interplay between FGF-2 and VEGF-C collaboratively stimulated
angiogenesis, intratumoral lymphangiogenesis, tumor growth, and metastasis [76]. In
addition, FGF2 promotes vegf-c dependent lymphangiogeneis and knockdown of FGF2
inhibited lymphangiogenesis in vitro and in vivo [77].
GBX2 (gastrulation brain homeobox 2) gene silencing has an inhibition effect on
invasion, proliferation and angiogenesis by inhibiting the activation of the Wnt/β-catenin
signaling pathway in breast cancer cells [78].
These results suggest that the downregulated expression of various lymphangiogenesis-
related genes may be related to the decreased function of LECs derived from preeclamp-
tic pregnancies. Changes in the expression of these genes in the umbilical cord blood
from PE may be the basis for explaining why offspring of women with PE during preg-
nancy are more likely to develop various diseases. However, the detailed mechanism of
how the downregulation of these lymphangiogenesis-related genes affects the function of
preeclamptic pregnancy-derived LECs remains to be resolved.
To our knowledge, this is the first study to demonstrate the impaired functions
and dysregulated lymphangiogenesis of LEPCs derived from cord blood of preeclamptic
pregnancies in vitro and in vivo. Our study also improves the current understanding of the
fetal origin of disease in response to PE and in utero programming. While the majority of
studies on dysfunctional lymphangiogenesis focus on cancer metastasis, the current study
suggests the plausible involvement of lymphangiogenesis in the pathogenesis of chronic
diseases such as cardiovascular and metabolic disorders. We also provide information
about potential therapeutic targets for long-term PE-related complications in mothers
and offspring.
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4. Materials and Methods
4.1. Study Population and Sample Collection
We enrolled subjects that delivered either vaginally or by cesarean section at 36–41
weeks of gestation at Severance Hospital between September 2016 and July 2017. The
umbilical cord blood was obtained for VEGFR3+/Pod+/CD11b+ LEPC isolation at the
time of delivery after fetal expulsion from women with PE (n = 10) and those with nor-
mal pregnancies (n = 10) (Table 1). The women assigned to the “PE” group exhibited
severe PE comprising hypertension (defined as a blood pressure level >160/110 mmHg
on two occasions at least 4 h apart during bed rest) in association with thrombocytopenia
(indicated by a platelet count <100,000/µL), impaired liver function (indicated by a 2×
elevation from normal levels of liver enzyme blood concentrations), severe persistent
right-upper quadrant or epigastric pain that was unresponsive to medication and/or not
accounted for by an alternative diagnosis, progressive renal insufficiency (indicated by
a serum creatinine concentration >1.1 mg/dL or a 2× elevation in the serum creatinine
concentration in the absence of any other renal disease), pulmonary edema, and/or new-
onset cerebral and/or visual disturbances, as per the American College of Obstetricians
and Gynecologists guidelines [79,80]. Pregnancies associated with premature membrane
rupture, fetal malformation, chromosome anomalies, multiple pregnancies, and/or renal or
endocrine diseases other than diabetes mellitus were excluded from the study. All patients
provided informed consent before their participation in the study, which was approved by
the Institute Review Board of Severance Hospital (4-2016-1022) on 12 January 2017.
Table 1. Patient characteristics.
Normal Pregnancy (n = 10) Preeclampsia (n = 10) p Value
Maternal age (year) 33.4 ± 5.1 32.8 ± 3.4 0.658
Gestational age at
delivery (week) 39.1 ± 1.1 35.9 ± 2.2 0.583




pressure 114.6 ± 10.5 151.4 ± 15.1 <0.001
Diastolic blood
pressure 75.1 ± 7.5 94.6 ± 10.3 <0.001
Pre-pregnancy BMI
(kg/m2) 23.6 ± 4.9 22.2 ± 3.7 0.375
Birthweight (g) 3435 ± 457.0 2199.8 ± 654.8 <0.001
Small gestational
age newborn (n) 1 10 0.023
4.2. Isolation and Cultivation of LEPCs (VEGFR3+/Pod+/CD11b+ Cells)
Mononuclear cells were isolated from human umbilical cord blood samples (approx-
imately 50 mL each) by density-gradient centrifugation using Biocoll (Biochrom, Berlin,
Germany) for 30 min at 400× g. The samples were washed thrice in phosphate-buffered
saline (PBS; Biochrom), and the VEGFR3+/Pod+/CD11b+ cells were purified by positive
selection using anti-VEGFR3/Pod/CD11b microbeads (Miltenyi Biotec, Bergisch-Gladbach,
Germany) and a magnetic cell sorter device (Miltenyi Biotec). The purity was >98%, as
assessed by fluorescence-activated cell sorting (FACS). The VEGFR3+/Pod+/CD11b+ cells
were seeded into six-well plates coated with human fibronectin (Sigma, St. Louis, MO,
USA) in endothelial basal medium-2 (EBM-2; Clonetics, Cell Systems, St. Katharinen,
Germany). The medium was supplemented with endothelial growth medium-2 (EGM-2;
Clonetics, Cell Systems) containing fetal bovine serum (FBS), human VEGF-A, human
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fibroblast growth factor-B, human epidermal growth factor, insulin-like growth factor 1
(IGF1), and ascorbic acid at the recommended concentrations. Cultures were maintained
for 7 days, and phenotypic analyses of the cells were performed on day 3, 5, and 7.
4.3. LEPC Differentiation Assay
LEPCs (5 × 105 cells/well, n = 10) were seeded in six-well plates coated with fi-
bronectin (10 µg/mL; Sigma) and cultured in EGM-2. The medium was replaced every 2
days, and the morphological assessment of LECs was performed using light microscopy.
The differentiation day was calculated as the first day on which a differentiated LEC colony
was observed from the time of LEPC seeding. The differentiation day and number of
colonies formed in each set were determined using light microscopy. Ten cell lines were
used for the experiment.
4.4. In Vitro Tube Formation Assay
Tube formation was assayed as previously described [81]. Matrigel solution (250 µL)
(BD Biosciences, Bedford, MA, USA) was added to a 16 mm-diameter tissue culture well
and allowed to polymerize (30 min, 37 ◦C). LECs (1.2 × 105 cells/well) were resuspended
in EBM and plated onto Matrigel. Matrigel cultures were incubated at 37 ◦C and cells were
photographed at 16 and 24 h of incubation (200×magnification). The mature tube network
was determined by scanning photographs of the tubes into Adobe Photoshop. ImageJ
software (National Institute of Health) was used to quantify the identified areas.
4.5. Cell Proliferation Assay
LECs (1 × 103 cells) were seeded into a 96-well plate. The cells were cultured for
72 h and incubated with 20 µL of the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium
bromide (MTT; 5 mg/mL) reagent. After 4 h, the supernatants were removed, and the cells
were treated with 150 µL dimethyl sulfoxide (DMSO). The absorbance value (OD) of each
well was measure at a wavelength of 490 nm. The experiments were performed in triplicate
with three different cell lines.
4.6. Cell Migration Assay
Cell migration was assayed using the Transwell system (Corning Costar, Acton, MA,
USA) using 6.5 mm-diameter polycarbonate filters (8-µm pores). The lower surface of the
filter was coated with 10 µg/mL fibronectin (Sigma-Aldrich, St. Louis, MO, USA), and LECs
(105 cells) from passage 3 were seeded onto chemotaxis filters in EBM supplemented with
0.5% FBS. After 5 h incubation, non-migrating cells were removed and migrating cells were
analyzed by hematoxylin and eosin (H&E) staining. Quantification was performed using
Kodak 1D software (Eastman Kodak, Rochester, NY, USA). The results were performed in
triplicate with three different cell lines.
4.7. Wound Healing Assay
The wound healing was performed by scratching a confluent layer of LECs on 35-
mm dishes using a micropipette tip. The cells were then washed and captured at 0 and
16 h. For quantitative analysis, five fields per plate were photographed, and the distances
between the front lines were measured using ImageJ software (National Institutes of Health,
Bethesda, MD, USA). Each assay was performed in triplicate with three different cell lines.
4.8. Cell Matrix Adhesion
The cell matrix adhesion was performed as previously described [82]. 96-well plates
were coated with 10 µg/mL human fibronectin overnight at 4 ◦C (Sigma-Aldrich, St. Louis,
MO, USA). Then, 105 LECs were seeded and incubated for 30 min at 37 ◦C (100 µL
adhesion buffer comprising serum-free medium and EBM). After the nonadherent cells
were discarded, the adherent cells were stained with H&E. Quantification was performed in
triplicate by counting the adherent cells in five randomly selected fields per well (Axiovert
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100; Carl Zeiss Micro-Imaging, Thornwood, NY, USA). The results were performed in
triplicate with three different cell lines.
4.9. Three-Dimensional (3D) Bead Sprouting Assay
LECs were coated on Cytodex 3 microcarrier beads (ratio of 400 cells/bead: GE
Healthcare Bio-Sciences Corp, Piscataway, NJ, USA) in Microvascular Endothelial Cell
Growth Medium-2 MV (Lonza) and embedded in 2 mg/mL fibrin gels in 48-well plates by
mixing 2 mg/mL fibrinogen (Chemicon Inc., Rolling Meadow, IL, USA) in HBSS, 1 U/mL
thrombin (Sigma-Aldrich, St. Louis, MO, USA), and 150 µg/mL aprotinin (Sigma-Aldrich,
St. Louis, MO, USA). WI-38 cells (11,000 cells/well) were cultured for 5 days by changing
the medium every other day. Sprouted LECs were fixed with 4% paraformaldehyde for 1 h
at room temperature (20 to 25 ◦C). Bright-field images were captured using Axiovert 200
(Zeiss) at 5×magnification, and sprout lengths were measured using ImageJ software.
4.10. Three-Dimensional (3D) Spheroid Sprouting Assay
LECs (3000 cells) were cultured in round-bottom 96-well plates (Nunc, Rochester,
NY, USA) precoated with 0.8% agarose for 1 day and the spheroids were collected and
embedded in 20% Matrigel-containing (BD Biosciences) fibrin gels (3 mg/mL fibrinogen,
2 U/mL thrombin, and 200 µg/mL aprotinin). The spheroids were cultured for 48 h, fixed
with 4% paraformaldehyde for 1 h at room temperature, and stained with rabbit anti-
human lymphatic vessel endothelial hyaluronan receptor 1 (LYVE1) polyclonal antibody
(Abcam, Inc., Cambridge, MA, USA).
4.11. Immunofluorescence Staining
Confluent LECs were fixed with 3.7% formaldehyde for 20 min and permeabilized
with 0.1% Triton X-100 in PBS. The LECs were then preincubated with a blocking solution
of PBS containing 5% normal donkey serum and 0.05% Tween-20. The cells were incubated
with goat anti-VE-cadherin polyclonal antibody (1:100 dilution, Santa Cruz Biotechnology
Inc., Santa Cruz, CA, USA) for 2 h at room temperature (20 to 25 ◦C) and labeled with a
fluorescein-conjugated secondary antibody (Molecular Probes, Eugene, OR, USA). The
samples were observed under a fluorescence microscope (Olympus, Tokyo, Japan).
4.12. Transwell Permeability Assay
LECs were plated onto a Transwell filter (Corning, pore size: 3.0 µm, membrane
diameter: 6.5 mm) and cultured for two days. The lower chamber was filled with 0.6 mL
EBM, and serum-free EBM supplemented with 1 mg/mL fluorescein isothiocyanate (FITC)-
dextran (average MW ~40,000) was added to the top chamber. A 50-µL aliquot of EBM
was taken from the lower chamber at various time points, and the amount of FITC-dextran
diffused to the bottom chamber was measured using a fluorometer (FluorStar Optima,
BMG Labtech, Mornington, VIC, Australia) excitation: 485 nm; emission: 520 nm). The
experiments were performed in triplicate with three different cell lines.
4.13. LEC Differentiation Assay in Matrigel
Seven-week-old male C57/BL6 mice (Orient Company, Seoul, Korea) were subcuta-
neously injected with 0.6 mL Matrigel containing 1 × 105 human LEPCs. After 14 days, the
plugs were removed and washed with PBS. Then, 8 µm-thick frozen Matrigel sections were
blocked with 5% normal donkey serum in PBS containing 0.1% Triton X-100 and incubated
overnight with a primary antibody (anti-human LYVE1 (Abcam, Inc., Cambridge, MA,
USA) or anti-human podoplanin (R&D Systems, Minneapolis, MN, USA)) at 4 ◦C and
labeled with a fluorescein-conjugated secondary antibody (Molecular Probes). The sam-
ples were observed under a fluorescence microscope (Olympus). The numbers of LYVE1
and podoplanin double-positive differentiated LEPCs and lymphatic vessels within the
Matrigel were counted in six fields per section.
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4.14. RNA-Sequencing for Gene Expression Analysis
Total RNA was isolated using Trizol reagent (Invitrogen), and RNA quality was
assessed on an Agilent 2100 Bioanalyzer using the RNA 6000 Nano Chip (Agilent Technolo-
gies, Amstelveen, The Netherlands). RNA quantification was performed using an ND-2000
Spectrophotometer (Thermo Fisher Scientific Inc., Wyman Street Waltham, MA, USA).
For normal (n = 3) and preeclamptic (n = 3) pregnancy-derived LEC RNAs, library
construction was performed using QuantSeq 3′-mRNA-Seq Library Prep Kit (Lexogen, Inc.,
Wien, Austria) according to the manufacturer’s instructions. In brief, 500 ng total RNA
was prepared, hybridized with an oligo-dT primer containing an Illumina-compatible
sequence at its 5′-end, and subjected to reverse transcription. After degradation of the
RNA template, second-strand synthesis was initiated using a random primer containing an
Illumina-compatible linker sequence at its 5′-end. The double-stranded library was purified
using magnetic beads to remove all reaction components. The library was amplified to
add the complete adapter sequences required for cluster generation. The finished library
was purified from PCR components, and high-throughput sequencing was performed as
single-end 75 sequencing using NextSeq 500 (Illumina, Inc., San Diego, CA, USA).
QuantSeq 3′-mRNA-Seq reads were aligned using Bowtie2 [83]. The Bowtie2 in-
dices were either generated from the genome assembly sequence or the representative
transcript sequence to align the genome and transcriptome. The alignment file was
used to assemble the transcripts, estimate their abundances, and detect differential gene
expression. Differentially expressed genes were determined based on the counts from
unique and multiple alignments using coverage in BEDtools [84]. The read count (RC)
data were processed based on the quantile normalization method using EdgeR within
R [85] in Bioconductor [86]. Gene classification was based on searches performed using
DAVID (http://david.abcc.ncifcrf.gov/, accessed on 21 July 2018) and the Medline database
(http://www.ncbi.nlm.nih.gov/, accessed on 21 July 2018).
4.15. Real-Time Reverse-Transcription Quantitative Polymerase Chain Reaction (RT-qPCR)
Total RNA was isolated from the LECs derived from normal and preeclamptic preg-
nancies using Trizol reagent (Invitrogen, Carlsbad, CA, USA). Power SYBR Green RNA-to-
CTTM 1-Step kit (Applied Biosystems, Foster City, CA, USA) and StepOnePlusTM (Applied
Biosystems) were used to measure the mRNA expression of human genes according to the
manufacturer’s instructions. PCR conditions were as follows: 48 ◦C for 30 min and 95 ◦C
for 10 min, followed by 40 cycles of 95 ◦C for 15 s and 55 ◦C for 1 min. The results were
based on the cycle threshold (Ct) values. Differences between the Ct values for the experi-
mental and reference (GAPDH) genes were calculated, and the results are expressed as the
ratio of each RNA level to the calibrated sample. The primers used for gene amplification
are shown in Table 2.
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4.16. Statistical Analyses
All experiments were performed in triplicate with three different cell lines in each
group, and the data are presented as the mean ± standard error (SE). The statistical
comparison between groups was performed by one-way analysis of variance (ANOVA)
followed by Tukey’s test.
5. Conclusions
In conclusion, the present study demonstrates that LEPCs from PE displayed sig-
nificantly delayed differentiation and reduced formation of lymphatic endothelial cell
(LEC) colonies compared with the LEPCs from normal pregnancies. LECs from PE-derived
LEPCs exhibited decreased proliferation, adhesion, tube formation, migration, wound
healing, and 3D-sprouting activities compared with the normal pregnancy-derived LECs.
LECs derived from preeclamptic pregnancies also show increased permeability through
the disorganization of lymphatic VE-cadherin junctions. In vivo, LEPCs from PE showed
significantly reduced LEC differentiation and lymphatic vessel formation compared to the
LEPCs of the normal pregnancy.
Gene expression analysis revealed that compared to the normal pregnancy-derived
LECs, the PE-derived LECs showed a significant decrease in the expression of pro-
lymphangiogenic genes (GREM1, EPHB3, VEGFA, AMOT, THSD7A, ANGPTL4, SEMA5A,
FGF2, and GBX2). Overall, our findings demonstrate, for the first time, that LEPCs from
PE have reduced differentiation and lymphangiogenic activities in vitro and in vivo and
show decreased expression of pro-lymphangiogenic genes. This study opens a new avenue
for investigation of the molecular mechanism of LEPC differentiation and lymphangio-
genesis in the offspring of PE and subsequently may impact the treatment of long-term
health problem such as cardiovascular and metabolic disorders of offspring with abnormal
development of lymphatic vasculature.
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